1 Incredible Reason to Buy Pfizer Stock (PFE) in November

Pfizer (PFE) is presented as an attractive investment primarily due to its substantial 7% dividend yield, which has been amplified by a 35% stock decline over the past three years following reduced demand for its COVID-19 products. While the company's acquisition of Metsera, a weight-loss drug developer, raises concerns about a potential dividend cut similar to a past reduction, the article notes that even a halved payout would still offer a respectable 3.5% yield. Despite recent underperformance, Pfizer's low forward P/E of 8 and active drug pipeline suggest potential value for patient, income-focused investors.

Analysis

Pfizer (PFE) currently presents a substantial 7% dividend yield, significantly outperforming high-yield savings accounts. This elevated yield is largely a consequence of the stock's considerable underperformance, having declined over 35% in the past three years, contrasting sharply with the S&P 500's 84% rise. The primary driver for this slump has been the reduced demand for its COVID-19 vaccine and Paxlovid treatments following the initial pandemic boom.

Despite recent challenges, Pfizer trades at an attractive valuation with a forward P/E ratio of 8, notably below its five-year average of 10. The company maintains an active drug pipeline, which could yield future blockbuster products, and has a history of strategic acquisitions to bolster its portfolio. This suggests potential for long-term value for patient investors.

A key risk involves the potential for a dividend cut following the acquisition of weight-loss drug developer Metsera, a scenario that previously occurred after the Wyeth acquisition. However, even if the dividend were halved, the resulting 3.5% yield would remain respectable. Historical data from Hartford Funds indicates that dividend-paying stocks, particularly growers and initiators, have significantly outperformed non-payers and the broader market over the long term (1973-2024).

Key Decisions for Investors

• Investors focused on income should consider Pfizer's current 7% dividend yield, which offers a significant premium over high-yield savings accounts, especially in a declining interest rate environment.
• Acknowledge the risk of a potential dividend cut following the Metsera acquisition, though even a halved payout would still represent a respectable 3.5% yield.
• Evaluate Pfizer's long-term value proposition, considering its low forward P/E of 8 and active drug pipeline as potential catalysts for future appreciation despite recent stock underperformance.
• Monitor management's capital allocation strategy and integration progress of Metsera, as these factors will be crucial for dividend sustainability and future growth.